Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues.

Follin C, Karlsson S.

Endocr Connect. 2016 Jul;5(4):167-73. doi: 10.1530/EC-16-0038. Epub 2016 Jul 25.

2.

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.

Strasburger CJ, Karavitaki N, Störmann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR.

Eur J Endocrinol. 2016 Mar;174(3):355-62. doi: 10.1530/EJE-15-1042. Epub 2015 Dec 18.

3.

Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery.

Alvarez-Escola C, Cárdenas-Salas JJ, Pelegrina B, Sanz-Valtierra A, Lecumberri B.

Clin Case Rep. 2015 Nov;3(11):945-8. doi: 10.1002/ccr3.388. Epub 2015 Oct 7.

4.

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.

Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR.

Pituitary. 2016 Jun;19(3):235-47. doi: 10.1007/s11102-015-0684-z. Review.

5.

The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Plunkett C, Barkan AL.

Patient Prefer Adherence. 2015 Jul 30;9:1093-9. doi: 10.2147/PPA.S84887. eCollection 2015.

6.

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.

Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, Gadelha MR, Maisonobe P, Sert C, van der Lely AJ; LEAD Study Group.

Eur J Endocrinol. 2015 Sep;173(3):313-23. doi: 10.1530/EJE-15-0215. Epub 2015 Jun 5.

7.

Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis.

Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, Prokop LJ, Katznelson L, Murad MH.

J Clin Endocrinol Metab. 2014 Nov;99(11):4003-14. doi: 10.1210/jc.2014-2900. Epub 2014 Oct 30. Review. Erratum in: J Clin Endocrinol Metab. 2015 Jan;100(1):317.

8.

Patient-focussed outcomes in acromegaly.

Guitelman M, Abreu A, Espinosa-de-los-Monteros AL, Mercado M.

Pituitary. 2014 Jan;17 Suppl 1:S18-23. doi: 10.1007/s11102-013-0519-8.

9.

Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment.

Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B.

Int J Gen Med. 2013;6:31-8. doi: 10.2147/IJGM.S38594. Epub 2013 Jan 18.

10.
11.

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study.

Adelman DT, Burgess A, Davies PR.

Med Devices (Auckl). 2012;5:103-9. doi: 10.2147/MDER.S37831. Epub 2012 Dec 14.

12.

Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional.

Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J, Wall N, Grønbæk H, Florholmen J, Ohberg A, Granberg D.

Patient Prefer Adherence. 2012;6:703-10. doi: 10.2147/PPA.S34337. Epub 2012 Oct 17.

13.

Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits.

Carmichael JD.

Patient Prefer Adherence. 2012;6:73-82. doi: 10.2147/PPA.S20783. Epub 2012 Jan 18.

Supplemental Content

Support Center